NIDDA LYNX

Nidda Lynx is the parent holding company for STADA Arzneimittel AG, a leading European pharmaceutical manufacturer specializing in generics, specialty pharmaceuticals, and consumer healthcare products. Controlled by private equity firms Bain Capital and Cinven, the company operates a diverse portfolio that includes high-volume generics and a sophisticated pipeline of biosimilars and specialty therapies. STADA's strategic focus centers on three pillars: Consumer Healthcare, Generics, and Specialty Medicines, with key products in therapeutic areas such as oncology, neurology, and nephrology. The company maintains a significant global presence, providing affordable and high-quality medical solutions to patients across more than 120 countries. Through Nidda Lynx, the owners have overseen significant expansion and strategic restructuring of STADA's global operations since the 2017 acquisition.